| Document |
Document Title |
|
JP2011102240A |
To provide a novel compound that functions as an LXR antagonist and is useful to adult diseases, and a drug containing the compound.There are disclosed a tricyclic compound represented by formula (1) [in the formula, R1 represents a hydr...
|
|
JP2010518010T5 |
|
|
JP4683801B2 |
|
|
JP4648544B2 |
The invention relates to the compounds of formula: as well as to the salts thereof with inorganic or organic acids, to solvates thereof and/or to hydrates thereof, which have strong affinity and high selectivity for the human NK1 recepto...
|
|
JP4637584B2 |
Compounds having the formula (I) pharmaceutical compositions containing them and their methods of use for the treatment of neurological disorders related to amyloid ² protein production and neurological disorders such as Alzheimer's dis...
|
|
JP2011502133A |
This invention relates to compounds and methods for the inhibition of HDAC enzymatic activity. More particularly, the invention provides for compounds of formula (I), (I) and N-oxides, hydrates, solvates, pharmaceutically acceptable salt...
|
|
JP4613366B2 |
The present invention relates to new compounds represented by Formula I: wherein M represents a macrolide subunit of the substructure II: L represents the chain of the substructure III: -X 1 -(CH 2 ) m -Q...
|
|
JP2010285442A |
To provide a vasopressin V1a receptor antagonist useful as a therapeutic agent for such as dysmenorrhea (primary dysmenorrhea and/or secondary dysmenorrhea), early labor pain, hypertension, Raynaud's disease, cerebral edema, motion sickn...
|
|
JP2010248216A |
To provide a compound useful for treatment of neurological disorders relevant to formation of amyloid β protein and of neurological disorders such as Alzheimer's disease.There is disclosed the compound having a structure expressed by fo...
|
|
JP4575667B2 |
The present invention provides compounds having formula (I), and additionally provides methods for the synthesis thereof and methods for the use thereof in the treatment of various disorders including inflammatory or autoimmune disorders...
|
|
JP2010533717A |
The present invention relates to methods of promoting wakefulness in an individual by administering a carbamoyl ester or a pharmaceutically acceptable salt thereof.
|
|
JP4542311B2 |
A compound which comprises a backbone having a plurality of chiral carbon atoms, the backbone bearing a plurality of ligands each being individually bound to a chiral carbon atom of the plurality of chiral carbon atoms, the ligands inclu...
|
|
JP4540704B2 |
Immunoassays for the detection of everolimus are provided. Compounds for producing antibodies for everolimus, as well as antibodies produced therefrom, are also provided.
|
|
JP4528901B2 |
This invention provides a compound of the formula (I): a pharmaceutically acceptable salt or solvate thereof, wherein R 1 is optionally substituted lower alkyl, Y is -S(O)n- wherein n is 1 or 2, or -CO-, R 2 is hydrogen or lower alkyl, R...
|
|
JP4510021B2 |
The invention relates to benzoxazepinone derivatives of formula wherein R1, R2, R3, R4, and n are as defined in the specification and to a pharmaceutically suitable acid addition salt thereof. These compounds are good gamma-secretase inh...
|
|
JP4491131B2 |
Disclosed are thiazolobenzoheterocycles of the general formulaIncluding their isomers, racemates, enantioners and salts thereof, as well as processes for preparing these compounds and medicaments containing them. Also disclosed are novel...
|
|
JP2010520237A |
The present invention is directed to substituted benzodiazepinones, benzoxazepinones and benzothiazepinones compounds that are sodium channel blockers useful for the treatment of chronic and neuropathic pain. The compounds of the present...
|
|
JP2010518010A |
Compounds that inhibit cholinesterase activity and, upon hydrolysis release a pharmacologically active agent. The compounds of the invention are employed in methods to treat an individual. The pharmacologically active agent obtained by h...
|
|
JP4458514B2 |
A method for producing highly pure enamines, which comprises a step of reacting an aldehyde or ketone with an amine and a step of treating the resulting reaction mixture with an acidic aqueous solution at between 0 DEG C and 30 DEG C.
|
|
JP4426792B2 |
|
|
JPWO2008053913A1 |
General formula (I):[In the formula, R1Is the expression:(R26And R28Are lower alkyloxys, etc., each of which may be substituted independently; n1Is a group represented by (an integer of 0 to 3); Z may be substituted or may intervene with...
|
|
JP2009541331A |
The present invention provides methods for production and purification of active chromoproteins produced by Actinomadura sp. 21G792. The chromoproteins are useful for developing pharmaceutical compositions and treating diseases such as c...
|
|
JP2009539881A |
Substituted phenyl acetic acid compounds of formula I, pharmaceutical compositions, methods for their preparation and methods are provided that are useful in the treatment and prevention of disorders or conditions responsive to DP-2 rece...
|
|
JP2009538281A |
A process for the racemisation of a compound which is nefopam or an analogue thereof in the form of a single enantiomer or non-racemic mixture, which comprising contacting the compound with an acid.
|
|
JP2009537616A |
The present invention relates to 2-alkoxy-3,4,5-trihydroxyalkylamide derivatives, to pharmaceutical compositions comprising such compounds, to methods of treatment comprising administering such compounds, to processes for the preparation...
|
|
JP2009221230A |
To provide a new compound having NPY Y5 receptor antagonist activity.The compound of formula (I): R1-Y-N(-R2)-X-N(-R7)-Z [wherein R1 is an optionally substituted lower alkyl; Y is -S(O)n- (wherein n is 1 or 2) or -CO-; R2 is hydrogen or ...
|
|
JP4332112B2 |
The present invention relates to compounds that are capable of inhibiting, modulating and/or regulating signal transduction of both receptor-type and non-receptor type tyrosine kinases. The compounds of the instant invention possess a co...
|
|
JP4319245B2 |
This invention is directed to a compound of formula I, wherein R1, R2, R4, R5, R6, R7, R8 and n are as defined herein, or a pharmaceutically acceptable salt thereof; a pharmaceutical composition containing a compound of formula I, a proc...
|
|
JP2009529518A |
The invention provides a new method for treating disorders associated with activation of the Notch signal transduction pathway comprising administering an effective amount of a compound of Formula (I), in free form or in a pharmaceutical...
|
|
JP4307377B2 |
The present invention provides a compound of the formula: a pharmaceutically acceptable salt or a prodrug thereof, where R1, R2, R3, R4, R5, R6, R7, R8, R9, Y, Z1, m, n, and p are as defined herein. The present invention also provides co...
|
|
JP2009527575A |
Compounds are disclosed that have a formula represented by the following: Formula (I). The compounds may be prepared as pharmaceutical compositions, and may be used for the prevention and treatment of a variety of conditions in mammals i...
|
|
JP2009522225A |
The invention relates to novel macrocyclic compounds of the formula in which all of the variables are as defined in the specification, in free base form or in acid addition salt form, to their preparation, to their use as medicaments and...
|
|
JP4261365B2 |
Provided is a method for obtaining a macrolide, especially tacrolimus, from biomatter.
|
|
JP2009511589A |
The invention relates to novel compounds and methods of treating diseases, disorders, and conditions associated with amyloidosis. Amyloidosis refers to a collection of diseases, disorders, and conditions associated with abnormal depositi...
|
|
JP2009051822A |
To provide an effective sustained release version of GABA analogs so as to minimize the increase of the administering frequency of many -aminobutyric acid (GABA) analogs including gabapentin requiring frequent administrations because of ...
|
|
JP4219166B2 |
The invention relates to novel benzazepines and related heterocyclic derivatives (I) and their use as active ingredients in the preparation of pharmaceutical compositions. The invention also concerns related aspects including processes f...
|
|
JP2009502898A |
Nefopam is used for the manufacture of a medicament for the treatment of an affective disorder such as ADD or ADHD.
|
|
JP4216713B2 |
The present invention provides prodrugs of GABA analogs, pharmaceutical compositions of prodrugs of GABA analogs and methods for making prodrugs of GABA analogs. The present invention also provides methods for using prodrugs of GABA anal...
|
|
JP2009501705A |
The present invention relates to new compounds of formula (I), or salts, solvates or solvated salts thereof, process for their preparation and to new intermediates used in the preparation thereof, pharmaceutical compositions containing s...
|
|
JPWO2006132295A1 |
Provided are a compound represented by the following formula (1) or a prodrug thereof, or a pharmaceutically acceptable salt thereof, which exhibits a preventive or therapeutic effect on various diseases such as hypertension, stroke and ...
|
|
JP2009500406A |
The present invention relates to new compounds of formula I, or salts, solvates or solvated salts thereof, process for their preparation and to new intermediates used in the preparation thereof, pharmaceutical compositions containing sai...
|
|
JP2008297317A |
To provide a new analogue of F152.The invention provides compounds having formula (I), and methods for the synthesis of the compounds and methods for treatment of various disorders (including inflammatory disorders, autoimmune disorders,...
|
|
JP2008540395A |
The present invention is directed to compounds of formula (I), and pharmaceutically acceptable salts and solvates thereof, their synthesis, and their use as HSP-90 inhibitors.
|
|
JP2004516324A5 |
|
|
JP4181291B2 |
A compound comprising a substituent of the formula (II) is disclosed as an HIV protease inhibitor. Intermediates for making such compounds and processes for making such intermediates are also disclosed.
|
|
JP4180121B2 |
PCT No. PCT/JP98/03153 Sec. 371 Date Nov. 24, 1999 Sec. 102(e) Date Nov. 24, 1999 PCT Filed Jul. 14, 1998 PCT Pub. No. WO99/03847 PCT Pub. Date Jan. 28, 1999A process for producing 4-substituted-3-halogeno-1,4-benzoxazepin derivative or ...
|
|
JP2008538750A |
The invention provides compounds of the formula (I): or salts, tautomers, solvates and N-oxides thereof; wherein R 1 is hydroxy or hydrogen; R 2 is hydroxy; methoxy or hydrogen; provided that at least one of R 1 and R 2 is hydroxy; R 3 i...
|
|
JP2008534497A |
The present invention provides novel 1,4-benzothiazepine intermediates and derivatives, methods for synthesizing same, and methods for assaying same. The present invention also provides methods for using these novel compounds to limit or...
|
|
JP2008534663A |
Nefopam or an analogue thereof is useful in the treatment of a syndrome characterized by chronic pain and fatigue.
|
|
JP2008532992A |
A compound selected from (1S)-8-cyano-5-methyl-1-(3-methoxy)phenyl-1,3,4,6-tetrahydro
-5H-benz[f]-2,5-oxazocine; (1R)-8-cyano-5-methyl-1-(3-methoxy)phenyl-1,3,4,6-tetrahydro
-5H-benz[f]-2,5-oxazocine; (1S)-8-cyclopropyl-5-methyl-1-(3-met...
|
